Sofinnova Partners Closes $815M Crossover II Fund
Manufacturing plans and market access enter the investment conversation while a therapy is still being tested. For Sofinnova Partners, that overlap helps explain the purpose of Crossover II, a fund designed to finance life-sciences companies as clinical evidence develops into a broader commercial proposition.
On November 16, 2026, the European investment manager announced Crossover II's final close at €725M, equivalent to $815M in its release. The vehicle exceeded its original target and plans to support approximately 15 companies, principally European clinical-stage biopharma and medtech businesses, with selective investments in the US and other markets.
The financing puts more capital behind an investment practice that follows development maturity across public and private companies. Its relevance for a founder starts with the next clinical or operating decision: whether the company has evidence strong enough to attract this kind of owner, and a plan for carrying that evidence toward commercial readiness.
Clinical development shapes the investment mandate
Sofinnova's Crossover strategy focuses on companies with initial proof of concept. That gives the team a selection criterion rooted in the development program itself, rather than a financing label that can mean different things across businesses. The strategy can invest in public as well as private companies, leaving room for the investment relationship to span a change in ownership setting.
Cedric Moreau, a Crossover Partner, explains that clinical stage and proof of concept guide the team's decisions. His background includes life-sciences investment banking and healthcare equity research, experience with both companies seeking capital and investors deciding what their evidence is worth. The practical implication is an investor-fit conversation that begins with the program's maturity, then works outward to financing and commercial options.
For a management team, those are connected assignments. Clinical development generates information that can change the company's choices, while manufacturing, management capacity and financing have to be prepared around the next decision. Reading this mandate as an automatic invitation to any late-stage company would miss the selection work inside it. A founder has to explain what the evidence supports today and what the next investment is intended to establish.
The partners bring different parts of the company into view
The Crossover strategy is led by Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat and David Evans. Antoine Papiernik is Sofinnova Partners' Chairman and Managing Partner. These roles matter because the announcement concerns a specialist investment vehicle inside a broader management firm, with a named team responsible for its strategy.
Kinam Hong's biography connects public-biotech investing with earlier product-development work at Sanofi. He describes meaningful ownership and board involvement as ways to influence the company's decisions. That perspective gives the fund's public-and-private remit an operating dimension: ownership can come with an active role while the development program continues.
David Evans, who joined the team in June 2026, brings experience across clinical development, market access and health economics. His career includes the Roche Venture Fund and work supporting Roche's neuroscience and rare-diseases pipeline. Those disciplines put the eventual route to patients alongside the scientific question, without turning a financing announcement into a prediction of approval or commercial success.
Jacques Theurillat describes diligence extending through clinical programs, intellectual property, manufacturing, management and boards. For operators approaching the team, that breadth suggests preparation across the company. The people answering questions about production or organizational readiness can become part of the financing conversation well before a product reaches the market.
A larger successor, with investment work already underway
Sofinnova's March 3, 2021 announcement recorded the predecessor's final close at €445M. On a like-currency basis, Crossover II is approximately 63% larger. That calculation compares the sizes of two vehicles; it supplies no measure of investment returns or the amount still available for new deals.
The new fund has already backed Hemab Therapeutics, CellCentric and Neurent Medical, according to the manager. The European Tech Champions Initiative, a fund of funds managed by the European Investment Fund, is a named backer. The announcement leaves the original numeric target, full limited-partner roster, commitment allocations and check sizes undisclosed.
Hemab offers a concrete example of the continuing development work in this portfolio. In a November 9 company release hosted by Sofinnova, Hemab announced initiation of SOLARA, its pivotal Phase 3 trial of investigational sutacimig for Glanzmann thrombasthenia. The announcement describes a study beginning, with evidence still to be collected. It gives the fund story a clinical timetable without supplying an investment allocation or an outcome.
That distinction keeps the capital useful to readers. Approximately 15 planned holdings describes intended portfolio scope, while the work inside each company will determine how it uses financing. Dividing the final close by that number would manufacture an investment policy the manager has not disclosed. DevCuration's coverage of NeoSci Ventures' first close offers a separate biotech-fund example of why the announced fundraising stage belongs alongside the headline amount.
What clinical-stage founders can take into the conversation
Crossover II gives European biopharma and medtech teams a more specific investor proposition to assess. The firm is seeking development evidence and a path toward commercial readiness, with selective international scope. A company can use that published mandate to decide whether the conversation belongs on its financing agenda, rather than treating the headline amount as an invitation by itself.
The preparation follows naturally from the team's stated approach. Management needs to connect the clinical program with manufacturing plans, intellectual property and the people responsible for the next stage. An explanation of what new evidence would change is more useful here than an ambitious round label. It gives both sides something concrete to evaluate before a financing structure takes shape.
For the fund's backers, the larger successor places more capital behind that selection and ownership model. For the companies it supports, the relationship will develop through the trial, board and commercial decisions that follow. As Crossover II builds toward its planned portfolio, those decisions will give the announced mandate its company-by-company substance.
Biotech funding, last 30 days
DevCuration's funding database tracked 15 Biotech rounds totaling $1.3B in disclosed capital over the past 30 days. Recent deals we covered:
- Neurosterix Raises $105M for Schizophrenia Phase 2 PlansSeries B · $105M · Nov 14
- Araceli Biosciences Raises $4.5M for Cell Imaging Growth$4.5M · Nov 13
- MaxCyte Plans $151.8M Akron Bio Deal for Cell TherapyM&A · $151.8M · Nov 12
- Dechra Agrees to Acquire Gallant's Cell-Therapy PlatformNov 10
- Yosemite Closes $350M Fund II for Cancer Research and CareFund II · $350M · Nov 9
Frequently Asked Questions
What makes a clinical-stage company a fit for Sofinnova Crossover?
The published strategy focuses on clinical-stage biopharma and medtech companies with initial proof of concept. It considers development maturity and supports progress toward clinical milestones and commercial readiness, primarily in Europe with selective international investments.
Can Sofinnova Crossover invest in publicly listed companies?
Yes. Sofinnova describes the Crossover strategy as investing in both public and private clinical-stage companies. A company's development program and proof of concept are central to its stated selection approach.
Does the final-close amount reveal how much each company will receive?
No. The manager plans approximately 15 investments, but the announcement does not disclose individual check sizes, reserves or remaining deployable capital. The final-close amount is the total size of Crossover II.
How does Crossover II compare with the predecessor fund?
Crossover II closed at €725M, versus the predecessor's €445M final close announced on March 3, 2021. The new vehicle is approximately 63% larger on a euro-denominated basis; that comparison does not measure investment returns.
Which kinds of preparation extend beyond clinical evidence?
The Crossover team's published biographies describe diligence spanning intellectual property, manufacturing, management and boards, alongside experience in clinical development and market access. These areas help explain the operating preparation relevant to the strategy's commercial-readiness mandate.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved